Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer

Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer have?

Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer has 544 citations in the OpenAlex counts ScholarIQ stores.

When was Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer published?

Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer has 2020 year in the ScholarIQ index.

What is the open-access status of Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer?

Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer has closed oa status in the ScholarIQ index.

What is the DOI of Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer?

The DOI for Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer is on the source record.

What is the PMID of Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer?

The PMID for Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer is on the source record.

What is the OpenAlex record for Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer?

The OpenAlex for Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer is on the source record.